CAR-T cell therapy

Caribou Biosciences (CRBU) will host a webcast on November 3, 2025, to report clinical data from the ANTLER Phase 1 trial of vispa-cel (CB-010) in relapsed/refractory B-NHL and first-time clinical data from the CaMMouflage Phase 1 trial of CB-011 in relapsed/refractory multiple myeloma. The Company will also outline the Phase 3 trial design for vispa-cel and development plans for CB-011. The webcast will be available live and archived on Caribou’s website.

Fate Therapeutics reported positive Phase 1 data for FT819, an off-the-shelf CAR T-cell therapy, in ten treatment-refractory SLE patients. A single dose resulted in rapid B-cell depletion and immune remodeling. The study showed durable clinical responses, including complete renal responses and steroid-free remission. FT819 demonstrated a favorable safety profile with low-grade CRS and no ICANS or GvHD. The data support potential outpatient administration and a pivotal study in 2026. These results suggest FT819’s transformative potential for SLE treatment.

Kyverna Therapeutics will present interim Phase 2 KYSA-6 trial results for KYV-101 in myasthenia gravis at the AANEM meeting in October 2025. Data from six patients with up to 9 months follow-up will be shared. KYV-101, a CD19 CAR T-cell therapy, aims for durable remission after a single dose. The study has been upgraded to a registrational Phase 2/3 trial, with Phase 3 initiation planned by year-end 2025. The presentation by Dr. Srikanth Muppidi will be on October 29th.

Hemogenyx Pharmaceuticals secured £620,000 through convertible loan notes (CLNs) to fund the clinical trial of HG-CT-1, a CAR-T cell therapy. Issued at £5.30 per share, the non-interest bearing CLNs will automatically convert into 116,982 Ordinary Shares around November 15, 2025, following eased headroom restrictions under FCA Prospectus Rules. The funding supports the ongoing Phase I trial for relapsed or refractory acute myeloid leukemia. The new shares will be admitted to trading on the London Stock Exchange.

Hemogenyx Pharmaceuticals (LSE:HEMO, OTC:HOPHF) has successfully treated the third patient in its Phase I clinical trial of HG-CT-1, a CAR-T cell therapy for relapsed/refractory acute myeloid leukemia (R/R AML), completing the first adult dose cohort. The FDA granted special permission for the treatment. The first two patients remain alive at six and three months post-treatment. Hemogenyx plans to initiate a second adult dose cohort and a pediatric trial arm, evaluating safety and anti-leukemic activity.